Among the six recipients of the Damon Runyon-Dale F. Frey Award, Dr. Fangtao Chi of MIT is delving into the nuanced interplay between dietary nutrients and cellular metabolism as they influence intestinal regeneration and tumorigenesis. His work focuses on how the intestine’s rapid self-renewal, mediated by intestinal stem cells, is affected by metabolic signals derived from diet. While these metabolic pathways promote tissue repair after damage such as inflammation or cancer therapy, Dr. Chi’s groundbreaking investigations also reveal that the same regenerative mechanisms can be subverted to fuel abnormal cellular growth, leading to tumors. By systematically dissecting these nutrient-metabolism pathways, Dr. Chi aims to establish dietary strategies that optimize tissue repair while mitigating colorectal and other intestinal cancers.

Dr. Cayla E. Jewett at the University of Colorado, Denver Anschutz Medical Campus is tackling an intriguing paradox presented by multiciliated cells. These specialized cells generate an abundance of centrioles—cellular organelles ordinarily tightly regulated to prevent cancerous transformation. Surprisingly, multiciliated cells manage to safely increase centriole numbers and use the DNA damage response pathway normally associated with oncogenic stress as part of their development. Dr. Jewett’s research seeks to decode how such cells reconcile these contradictory features, hoping to uncover novel molecular checkpoints that prevent tumorigenesis. Insights from this research may identify new therapeutic targets that inhibit abnormal centriole amplification in cancer cells while sparing normal tissue.

At Princeton University, Dr. Titas Sengupta investigates how epigenetic modifications of histones—proteins around which DNA is wrapped—influence gene regulation in neurons, especially regarding aging and environmental responses. Her work has unveiled mechanisms by which rapid histone modifications modulate neuronal functions such as short-term memory, highlighting that dynamic gene expression changes rather than static protein reserves underlie these cognitive processes. This line of inquiry is highly relevant to understanding the epigenetic dysregulation often observed in cancers affecting nervous tissues, providing a potential framework for uncovering how altered chromatin landscapes contribute to cancer progression and neurological dysfunction.

Dr. Dylan M. Parker of the University of Colorado, Boulder studies stress granules—membraneless molecular condensates that form within cells under stress conditions, impacting gene expression and cell survival. Stress granules are garnering attention for their roles in cancer, particularly in how their dynamics could promote tumor progression and resistance to chemotherapy. Dr. Parker aims to elucidate the molecular controls governing stress granule assembly and disassembly, advancing our understanding of how cancer cells adapt to treatment. Such knowledge might open avenues for developing drugs that disrupt granule formation, thereby sensitizing resistant tumors to existing therapies.

At the University of Pennsylvania, Dr. Catherine Triandafillou explores error correction mechanisms during early development using gastruloids, three-dimensional stem cell clusters that mimic embryonic patterning. Her microscopy-enabled lineage-tracing studies assess how deviations in cellular behavior impact developmental outcomes and the capacity of tissues to correct aberrations. Understanding how these processes fail in cancer could illuminate why tumors contain abnormal cellular compositions and proliferate unchecked. Dr. Triandafillou’s work aims to uncover cellular and tissue-level responses to early developmental errors, potentially revealing new approaches to target cancer’s root defects.

Dr. Youngmu (Nick) Shin from UCSF is pioneering the engineering of scaffold proteins to reconstruct and probe cell-cell communication interfaces known as synapses. By building synthetic synapses through designed protein condensates, he strives to elucidate the physical principles governing synaptic organization and strength. Insights from this synthetic biology approach have profound implications for immunotherapy, including engineering immune cells like T cells to form precise, robust connections with cancer cells, enhancing their ability to target malignancies while minimizing damage to healthy tissues.

The November 2025 cohort of Damon Runyon Fellows also exemplifies the breadth and depth of current cancer research. Dr. Duaa H. Al-Rawi at Memorial Sloan Kettering focuses on the earliest genetic disruptions in high-grade serous ovarian cancer, particularly alterations in the p53 tumor suppressor pathway and chromosomal instability in fallopian tube cells. By modeling these initial events, her research aims to inform early detection and prevention strategies for this deadly cancer subtype.

Dr. Tatsat Banerjee from the Whitehead Institute investigates the fundamental signaling architecture within CAR T cells—immune cells genetically reprogrammed for cancer therapy—seeking to enhance their ability to recognize and persist against solid tumors like melanoma. His innovative melding of molecular genetics and biophysics targets improvements in the immunological synapse’s function, essential for T cell-mediated tumor eradication.

Leukemia translation regulation is the focus for Dr. Elizabeth Black, also at the Whitehead Institute. Her research zeroes in on translation start site selection, a nuanced control point of protein synthesis that is dysregulated in blood cancers but overlooked due to experimental challenges. Understanding how cancer cells manipulate translation initiation could herald novel therapeutic interventions.

At UCSF, Dr. Sarah W. Cai investigates how TRP ion channel receptors, key mediators of pain, form nanoscale clusters in sensory neurons during cancer-associated pain and chemotherapy-induced neuropathy. Her work employs advanced microscopy to parse receptor organization changes that amplify pain signaling, with prospects for designing better pain management approaches for cancer patients.

The interplay between diet-derived xenobiotics and inflammation in cancer progression forms the basis of Dr. Esther J. Han’s work at Yale University. She studies how gut microbes and host cells chemically modify these plant-derived molecules, influencing cancer risk and inflammation, potentially guiding nutritional interventions to prevent or mitigate disease.

Dr. Qixiang He at Columbia University explores a novel bacterial antiviral defense that synthesizes DNA rather than cleaving it. By deciphering this system’s mechanisms, his research aims to develop innovative gene therapy delivery methods that circumvent immune reactions, potentially enhancing gene- and immunotherapies in cancer treatment.

Dr. King L. Hung at The Scripps Research Institute employs the regenerating flatworm as a model to study how chemical and mechanical signals integrate to maintain tissue integrity, a property lost in cancer. His live imaging approaches seek to untangle the multicellular circuitry that prevents unchecked proliferation and invasion.

Protein complexes essential for lung cancer progression are the subject of Dr. Jinho D. Jeong’s research at Massachusetts General Hospital. Using Molecular COUPLrs, a novel chemical biology technology, he aims to selectively disrupt complexes driving non-small cell lung cancers and brain metastases, potentially revealing new drug targets for these lethal diseases.

At the Broad Institute, Dr. Wenbin Mei studies the influence of inherited genetics on the development and aggressiveness of ERBB2-driven cancers, such as breast and lung cancers. His work aims to integrate germline and tumor genomic data to personalize risk prediction and therapy.

Dr. Rishi Kumar Mishra at the University of Michigan focuses on how the motor protein dynein localizes at microtubule plus-ends during cell migration, a process critical for cancer metastasis. Understanding this mechanism may identify vulnerabilities to inhibit cancer spread.

Dr. Christian G. Peace from Princeton University has developed novel in vivo technology for tracking nutrient utilization by cancer and immune cells within the tumor microenvironment. His work sheds light on the metabolic competition in tumors influencing immunotherapy efficacy.

Dr. Juntao Yu at Whitehead Institute investigates chromatin-based mechanisms guiding asymmetric cell division in stem cells, fundamental for tissue homeostasis and cancer prevention. Dissecting chromosome inheritance patterns may reveal how cancer cells bypass these controls.

Finally, Dr. Ming M. Zheng at the Broad Institute integrates large-scale genetics, single-molecule imaging, and AI to create dynamic maps of oncogene behavior in living cells, aiming to guide the creation of precise and long-lasting cancer therapies with minimal side effects.

Together, these fellows and awardees represent a vanguard of cancer research, tackling fundamental questions with cutting-edge tools across genetics, cell biology, immunology, and bioengineering. Their combined efforts underscore the Damon Runyon Cancer Research Foundation’s commitment to nurturing innovative science that holds promise for transformative advances in cancer prevention, diagnosis, and treatment worldwide.

Subject of Research: Cancer research focusing on fundamental mechanisms of tumorigenesis, metastasis, immunotherapy, epigenetics, and cellular communication.

Article Title: Damon Runyon Foundation Announces 2026 Fellows and Breakthrough Scientists Driving Cancer Research Innovation

News Publication Date: 2025-11

Web References: http://damonrunyon.org/

Keywords: Cancer research, postdoctoral fellows, tumorigenesis, immunotherapy, epigenetics, cellular metabolism, stem cells, DNA damage, translation regulation, tumor microenvironment, cancer genetics, synthetic biology

Statins are primarily known for their ability to inhibit HMG-CoA reductase, a key enzyme in the mevalonate pathway responsible for cholesterol biosynthesis. This pathway’s dysregulation is not only central to metabolic disorders but also implicated in cancer pathogenesis through the modulation of cell proliferation, apoptosis, and metastasis. Lagunas-Rangel’s analysis delves into how the interference in this pathway by statins extends beyond lipid regulation, illustrating their potential impact on oncogenic signaling networks and tumor microenvironment dynamics.

One of the pivotal considerations highlighted involves the heterogeneity of cancer types and their metabolic dependencies. Statins may yield differential anti-cancer effects based on tumor genotype, phenotype, and microenvironmental context. For instance, tumors with aberrant activation of pathways reliant on prenylated proteins, such as Ras or Rho GTPases, may be more susceptible to the prenylation blockade induced by statins, resulting in impaired tumor growth and survival. This nuanced understanding calls for patient stratification guided by molecular profiling to optimize statin use in cancer therapeutics.

The review also emphasizes the pharmacokinetic and pharmacodynamic complexities when repurposing statins for oncological indications. Factors such as lipophilicity, serum half-life, tissue penetration, and metabolic stability markedly influence the bioavailability of statins in tumor tissues, thereby impacting therapeutic outcomes. Moreover, the intricate interplay between statins and other cancer treatments, including chemotherapy, targeted agents, and immunotherapy, invites careful evaluation to harness potential synergistic effects while mitigating adverse interactions.

Lagunas-Rangel elaborates on the immunomodulatory properties of statins, which could potentiate anti-tumor immune responses. By modulating inflammatory cytokine production and enhancing T-cell activity, statins may contribute to an immunological milieu unfavorable for tumor progression. Such effects present promising avenues for integrating statins into combination regimens aiming to amplify the efficacy of immune checkpoint inhibitors and other immunotherapeutic strategies.

Importantly, the review addresses the dosage and timing considerations vital for translating preclinical statin benefits into clinical success. While high doses may exert pronounced anti-cancer effects, they also raise the risk of toxicity and off-target effects, necessitating delicate balancing through rigorously designed clinical trials. Additionally, the temporal context of statin administration—whether as a preventive measure, during active treatment, or in the adjuvant setting—requires further elucidation to maximize positive therapeutic indices.

Genetic polymorphisms affecting statin metabolism and transport represent another layer of complexity in precision oncology. Variability in genes encoding cytochrome P450 enzymes and drug transporters can influence drug levels and response rates, reinforcing the need for pharmacogenomic assessment as part of personalized treatment planning. Incorporating such insights could mitigate interpatient variability and identify populations most likely to benefit from statin therapy.

Furthermore, Lagunas-Rangel’s review synthesizes evidence from epidemiological studies indicating an association between statin use and reduced cancer incidence or mortality in specific cohorts. However, the data remain inconclusive, often confounded by comorbidities, lifestyle factors, and study design limitations. This reinforces the necessity for well-controlled, prospective clinical trials explicitly targeting cancer outcomes with statins, guided by molecular biomarkers and patient selection heuristics.

One critical challenge underlined in the article is the need to unravel the mechanistic underpinnings of statin-induced anti-cancer effects in various tumor models. While apoptosis induction and cell cycle arrest are documented effects, emerging research points toward statin impact on cancer stem cell populations, angiogenesis inhibition, and modulation of tumor metabolism. Comprehensive molecular characterizations will be integral to clarifying these mechanisms and leveraging them therapeutically.

Additionally, the potential repurposing of statins invites economic and accessibility considerations. Given that statins are widely available and generally cost-effective, their adaptation for cancer treatment could alleviate financial barriers associated with novel oncology drugs, increasing treatment equity. However, this optimistic outlook hinges on rigorous validation of clinical benefits to substantiate inclusion in standard cancer care protocols.

Lagunas-Rangel’s examination also navigates the terrain of statin-related adverse effects, such as myopathy, hepatotoxicity, and glucose metabolism disturbances, which could complicate cancer therapy, particularly in patients with existing comorbidities or those receiving polypharmacy. The balance between maximizing anti-cancer efficacy and minimizing toxicities underscores the importance of vigilant monitoring and individualized dose adjustments in precision medicine frameworks.

The article further advocates for multidisciplinary collaborations encompassing oncologists, pharmacologists, molecular biologists, and bioinformaticians to decipher complex datasets and develop predictive models for statin responsiveness. Integrating high-throughput omics data with clinical parameters could pave the way for robust decision support systems, facilitating the rational incorporation of statins into personalized cancer treatment algorithms.

Finally, the review calls attention to future avenues including the design of novel statin derivatives or combination therapies engineered to enhance tumor-targeting capabilities while circumventing resistance mechanisms. Nanotechnology-based delivery systems and molecular conjugates hold promise for amplifying therapeutic indices and expanding the applicability of statins across diverse cancer subtypes.

In conclusion, the comprehensive review by Lagunas-Rangel articulates a compelling narrative positioning statins as potentially valuable components in the armamentarium of precision cancer medicine. By dissecting the biochemical, clinical, and pharmacological dimensions that modulate statin efficacy in oncology, the article lays the groundwork for informed clinical trial design and translational research endeavors. As the oncology community continues to embrace personalized approaches, understanding and harnessing the multifaceted roles of statins could significantly influence future cancer management paradigms.

Subject of Research: The role and implications of statins in precision cancer medicine, focusing on their biochemical mechanisms, clinical potential, and pharmacological considerations.

Article Title: Statins in the context of precision cancer medicine: important factors to consider.

Article References:
Lagunas-Rangel, F.A. Statins in the context of precision cancer medicine: important factors to consider. Med Oncol 42, 537 (2025). https://doi.org/10.1007/s12032-025-03101-9

Image Credits: AI Generated

PPARγ, a nuclear receptor with established roles in glucose metabolism and insulin sensitivity, has been extensively studied in metabolic disorders but only recently explored in the context of cancer biology. Its function as a transcription factor enables it to orchestrate a diverse array of cellular processes by modulating gene expression linked to lipid metabolism, inflammation, and cellular differentiation. Given this multifaceted influence, the protein represents a critical mechanistic node connecting metabolic regulation with cancer cell proliferation and tumor microenvironment dynamics.

The research team, headed by Professor Lukas Kenner, who serves as a visiting professor at Umeå University’s Department of Molecular Biology, conducted a retrospective clinical analysis combined with laboratory experiments on cell cultures and murine models. They specifically evaluated a cohort of 69 prostate cancer patients diagnosed with type 2 diabetes, under clinical surveillance at the Medical University of Innsbruck from 2014 to 2023. The team correlated treatment with pioglitazone, a thiazolidinedione-class PPARγ agonist, not only with prolonged relapse-free survival but also with metabolic reprogramming effects observed at the cellular level.

Pioglitazone exerts its biological activity by agonistically binding to PPARγ receptors, leading to altered transcriptional activity of target genes. This interaction changes signal transduction cascades involved in metabolic homeostasis and inflammation, which are pathways frequently hijacked by cancer cells to sustain unregulated growth and resist apoptosis. Interestingly, in studied prostate cancer cell lines, pioglitazone was able to suppress proliferative signals while simultaneously inducing metabolic shifts that weakened the energetic and biosynthetic capacity of the malignant cells, thereby hampering their growth potential.

The implications of these findings are profound because they suggest the possibility of repurposing an already-approved anti-diabetic medication as a component of prostate cancer management, particularly for patients with metabolic comorbidities. However, Professor Kenner emphasizes that while these preliminary clinical observations and preclinical data are promising, rigorous prospective clinical trials are essential to confirm efficacy, optimize dosing strategies, and evaluate whether similar benefits may extend to prostate cancer patients without diabetes.

Moreover, the potential dual action of pioglitazone—modulating both tumor metabolism and the inflammatory milieu—could represent a therapeutic paradigm that addresses tumor progression holistically. Chronic inflammation and altered metabolism are increasingly recognized as hallmarks of cancer, and targeting PPARγ may counteract malignant phenotypes by tipping the balance back toward cellular homeostasis and immune surveillance.

Importantly, variations in PPARγ function have been implicated in different cancer types, with evidence suggesting it might play contrasting roles depending on cancer context and cellular environment. In some malignancies, PPARγ activation might promote differentiation and slow growth, whereas in others, it may fuel tumorigenesis. Therefore, dissecting the molecular underpinnings within prostate cancer cells that enable pioglitazone’s anti-proliferative effects remains a critical area for future research.

The multi-institutional study involved collaboration across Austria, the Czech Republic, Germany, the United Kingdom, and Sweden, highlighting the growing trend of international cooperation in tackling complex diseases like cancer through integrative biomedical approaches. This pooling of expertise and resources has enabled a comprehensive investigation spanning epidemiological analysis, molecular biology, and pharmacology.

Clinically, prostate cancer represents one of the most frequently diagnosed malignancies in men worldwide, with treatment options ranging from surgery and radiation to hormone therapy and chemotherapy. Despite advances, recurrence and resistance remain challenging. The novel insight that a metabolic regulator like pioglitazone could contribute to delaying or preventing recurrence offers hope for expanding the therapeutic toolkit and improving long-term patient outcomes.

At the molecular level, the reprogramming of cancer metabolism induced by pioglitazone involves shifting energy production pathways, potentially restricting the availability of key substrates required for rapid cell division. These alterations may induce a metabolic bottleneck, curbing proliferation and sensitizing tumors to other interventions. Additionally, by modulating PPARγ, pioglitazone might attenuate pro-inflammatory signaling pathways that contribute to a tumor-promoting microenvironment.

Given the rising prevalence of type 2 diabetes worldwide, understanding the intersection between metabolic diseases and cancer biology is critical. This study exemplifies how drugs designed for metabolic disorders can be repurposed for oncological benefit, opening a new frontier in translational medicine focused on metabolism-centric therapies.

The authors note that while pioglitazone has known side effects primarily related to fluid retention and cardiovascular risk, the therapeutic balance may be favorable in prostate cancer patients with concurrent diabetes, where the drug’s benefits could outweigh its risks. Careful patient stratification and monitoring will be paramount in any future clinical trial design exploring this promising avenue.

In conclusion, this pioneering research suggests that the anti-diabetic drug pioglitazone offers a compelling candidate for prostate cancer treatment through its ability to inhibit tumor cell proliferation and induce profound metabolic reprogramming mediated by activation of PPARγ. This breakthrough not only highlights the intricate interplay between metabolism and cancer but also underscores the potential for existing pharmaceuticals to be harnessed in novel therapeutic contexts, heralding a new era of innovative, metabolism-targeted oncology.

—

Subject of Research: The role of the anti-diabetic PPARγ agonist pioglitazone in inhibiting prostate cancer cell proliferation and inducing metabolic reprogramming.

Article Title: The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer

News Publication Date: 5-May-2025

Web References: http://dx.doi.org/10.1186/s12943-025-02320-y

Image Credits: Medizinische Universität Wien

Keywords: pioglitazone, PPARγ, prostate cancer, metabolic reprogramming, type 2 diabetes, cancer metabolism, drug repurposing, tumor proliferation, inflammation, nuclear receptor, thiazolidinediones

Among the foremost scientific highlights is the work of Dr. M. Celeste Simon, Arthur H. Rubenstein Professor in Cell and Developmental Biology, who will explore the intriguing potential of targeting metabolic pathways as a modality for curing liver and other malignancies. Her talk, scheduled for April 26 in the Discovery Science Plenary session, underscores the growing appreciation of cancer cell metabolism—not simply as a consequence of tumorigenesis but as an active driver and therapeutic vulnerability. Simon’s research delves into how altered metabolic fluxes create metabolic dependencies that can be exploited to selectively eradicate tumor cells without harming normal tissue.

Complementing this metabolic focus, Dr. Shelley L. Berger—a distinguished molecular biologist and recipient of the AACR-Women in Cancer Research Charlotte Friend Lectureship—will deliver a keynote addressing epigenetic regulation and its profound implications for cancer progression and therapy. Dr. Berger’s investigations explore how dynamic chromatin states influence gene expression programs that fuel malignancy. Her pioneering work reveals how epigenetic modulators can be targeted to reverse aberrant transcriptional patterns, thereby restoring cellular controls lost during cancer evolution.

Equally compelling are presentations by Penn’s emerging scientific talents, particularly those centered on the intersection of metabolism and epigenetics in treatment-resistant cancers. Dr. Christina Demetriadou, from Dr. Kathryn E. Wellen’s laboratory, will report findings that elucidate how branched-chain amino acid metabolism contributes to histone propionylation in pancreatic cancer cells. This novel epigenetic modification links nutrient metabolism directly to chromatin remodeling, influencing tumor cell proliferation and survival. Unraveling this metabolic-epigenetic crosstalk offers a promising avenue to disrupt aggressive pancreatic ductal adenocarcinoma, a cancer notoriously refractory to conventional therapies.

In the realm of targeted therapeutics, graduate student Gianna T. Busch will present studies exploring the heterogeneous responses of therapy-resistant melanoma cells to second-line inhibitors. Melanomas harboring the BRAFV600E mutation frequently develop resistance to frontline BRAF inhibitors, prompting the need for innovative combination strategies to circumvent relapse. Busch’s work utilizes high-resolution genetic and phenotypic analysis to identify drug combinations that surmount resistance mechanisms, thereby improving durable responses against this formidable skin cancer.

Adding another dimension to cancer treatment, Margo I. Orlen will discuss breakthroughs in KRAS-targeted therapy in pancreatic cancer models, a domain long hampered by the ‘undruggable’ nature of RAS oncogenes. Orlen’s research, recently published in Cancer Discovery, demonstrates that RAS(ON) multi-selective inhibition not only impairs tumor growth but also reprograms the tumor microenvironment to enhance immune infiltration. By recruiting T cells and other immune effectors, this approach synergizes with immunotherapy, heralding a new paradigm for treating KRAS-driven malignancies.

Penn researchers are simultaneously advancing proteolysis-targeting chimera (PROTAC) technology to promote selective degradation of oncogenic proteins. Postdoctoral investigator Sehbanul Islam will reveal insights into the combinatorial application of VHL and KEAP1-based PROTACs, which show unanticipated synergy and mechanisms that alleviate the ‘hook effect’—a phenomenon that limits PROTAC efficacy at higher concentrations. These findings have fundamental implications for designing next-generation degraders with improved therapeutic windows and specificity.

Radiation oncology is also witnessing transformative innovation at Penn. Premed student Elias El Hoyek will present data demonstrating how FLASH proton radiotherapy—a technique delivering ultra-high dose rates of radiation—significantly reduces corneal damage and accelerates wound healing in murine models. These preclinical results herald a new era in radiotherapy that maximizes tumor eradication while minimizing damage to surrounding healthy tissue, a long-standing challenge in radiation oncology practice.

Bridging immunotherapy and nanotechnology, Dr. Khuloud Bajbouj’s research showcases the engineering of fibroblast activation protein (FAP)-directed CAR T cells via targeted lipid nanoparticles administered in situ. This novel delivery strategy enables robust, localized immune cell activation against the stromal components of pancreatic ductal adenocarcinoma, suppressing tumor progression. Such innovation exemplifies the increasing sophistication of tumor microenvironment-targeted therapies designed to overcome the immunosuppressive barriers erected by aggressive cancers.

In the genetics domain, postdoctoral researcher Mwangala Akamandisa will spotlight the tumor molecular landscape and therapeutic implications in young BRCA1/2 mutation carriers afflicted with breast cancer. These studies shed light on unique genomic profiles and vulnerabilities shaped by inherited mutations, informing tailored clinical management and precision oncology approaches for high-risk populations.

Together, these presentations reflect a broader thematic thrust at the AACR meeting to unravel the complexities of tumor biology through an integrated lens of metabolism, epigenetics, immunology, and therapeutic innovation. Penn Medicine’s contributions exemplify the power of multidisciplinary collaboration and cutting-edge biomedical research to generate transformative knowledge capable of driving next-generation cancer treatments.

The AACR Annual Meeting also provides a platform to honor distinguished leaders in the field. Dr. Shelley L. Berger’s recognition with the Charlotte Friend Lectureship highlights her seminal role in advancing cancer epigenetics and fostering women’s leadership in oncology. Additionally, the election of four Penn cancer researchers to the AACR Academy underscores the institution’s enduring prominence in the cancer research community.

As cancer continues to pose formidable challenges worldwide, the integration of novel scientific discoveries with translational strategies showcased by Penn Medical researchers offers hope for more effective, personalized, and less toxic therapies. The synergy between fundamental biology and clinical application present at this meeting exemplifies the trajectory toward curing cancers once deemed intractable.

In essence, the AACR 2025 Annual Meeting acts as a crucible for pioneering science, uniting researchers, clinicians, and trainees dedicated to decoding cancer’s complexity. The University of Pennsylvania’s robust representation affirms its commitment to transforming academic discoveries into clinical realities, thereby improving outcomes for patients confronting a spectrum of malignancies across the globe.

Subject of Research: Advances in cancer metabolism, epigenetics, immunotherapy, molecular oncology, and novel therapeutic approaches in diverse cancer types including pancreatic, melanoma, liver, and breast cancer.

Article Title: University of Pennsylvania Researchers Unveil Breakthroughs in Cancer Science at AACR Annual Meeting 2025

News Publication Date: April 2025

Web References:

• Abramson Cancer Center: https://www.pennmedicine.org/cancer
• Perelman School of Medicine: https://www.med.upenn.edu/
• AACR Annual Meeting 2025: https://www.aacr.org/meeting/aacr-annual-meeting-2025/
• Shelley Berger AACR Award: https://www.pennmedicine.org/news/news-releases/2025/april/shelley-berger-phd-honored-by-aacr-for-cancer-research
• M. Celeste Simon Profile: https://cdb.med.upenn.edu/people/m-celeste-simon-ph-d/

Keywords: Cancer research, metabolism, epigenetics, immunotherapy, KRAS inhibition, PROTACs, radiation therapy, CAR T cells, pancreatic cancer, melanoma, liver cancer, breast cancer, AACR 2025